Search the Newsreel

Edgewise Therapeutics (NASDAQ:EWTX) CEO Kevin Koch Sells 17,971 Shares of Stock

Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells 6,522 Shares

Edgewise Therapeutics CMO Joanne Donovan recently sold 6,522 shares of EWTX stock for $285,989.70 to cover tax withholding obligations on vested equity awards, reducing her holdings by 36.1%. Despite this insider sale and a quarterly earnings miss, the company's shares rose 2.3%, and analysts …

Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) Insider Sells 5,901 Shares

Edgewise Therapeutics (NASDAQ:EWTX) insider Alan Russell sold 5,901 shares of the company's stock on August 12th, 2026, totaling approximately $258,051. This sale was conducted to cover tax withholding obligations related to vested equity awards. Despite this insider selling, analysts maintain a "Moderate Buy" consensus …

Edgewise Therapeutics (EWTX) CSO gets 97,500-share equity awards, sells shares for taxes

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, reported equity transactions on August 12, 2026, which included exercising Restricted Stock Units and selling 5,901 shares to cover tax withholding obligations. Additionally, Russell received new equity awards comprising 32,500 RSUs and a stock option for …

Edgewise Therapeutics (NASDAQ:EWTX) General Counsel Sells $219,801.12 in Stock

Edgewise Therapeutics General Counsel John Moore sold 5,016 shares of EWTX stock worth $219,801.12 to cover tax withholding obligations from vested equity awards, reducing his direct ownership by 22.08%. The company's stock is trading near its 52-week high, and despite missing recent earnings expectations, …

Edgewise Therapeutics (EWTX) grants CFO 24,375 RSUs and 48,750-share option

Edgewise Therapeutics (EWTX) has granted its CFO, Michael Nofi, 24,375 Restricted Stock Units (RSUs) and an option for 48,750 shares of common stock. The RSUs vest in four equal annual installments starting August 12, 2027, and the stock options vest monthly over 48 months …

RA Capital’s 7.8% Edgewise Therapeutics (EWTX) stake totals 8.39M shares

RA Capital Management, L.P. and its affiliated parties have reported a 7.8% stake in Edgewise Therapeutics, Inc. (EWTX), totaling 8,392,730 shares of common stock. This ownership is held by RA Capital Healthcare Fund, L.P., with RA Capital having shared voting and dispositive power over …

Edgewise Therapeutics (EWTX) grants 50,000 RSUs and 100,000 options to CBO

Edgewise Therapeutics reported that its Chief Business Officer, Derakhshan Behrad, received equity awards comprising 50,000 Restricted Stock Units (RSUs) and a stock option for 100,000 shares. Behrad also had 5,781 and 7,500 RSUs convert into common stock on August 12, 2026, and subsequently sold …

Edgewise Therapeutics (EWTX): Baker Bros. discloses 3.4% ownership in Schedule 13G/A

Bank of America Corp DE Decreases Position in Edgewise Therapeutics, Inc. $EWTX

Edgewise Therapeutics, Inc. SEC Filing (Aug 13, 2026)

Edgewise Therapeutics, Inc. (EWTX) filed a Form 144 with the SEC on August 13, 2026, indicating a proposed sale of securities. The filing details the sale of 2,919 shares of common stock with an aggregate market value of $127,151.64 by an individual who acquired …

CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?

EWTX Maintains Neutral Rating - Price Target Raised to $36.00 by Goldman Sachs

Goldman Sachs has maintained a Neutral rating on Edgewise Therapeutics (EWTX) but increased its price target from $32.00 to $36.00. Despite the raised price target, the company's GF Score™ of 28/100, indicating financial challenges, and significant insider selling, suggest a cautious approach for investors. …

Edgewise Therapeutics, Inc. $EWTX Shares Acquired by California State Teachers Retirement System

The California State Teachers Retirement System increased its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 45.7% in the first quarter, acquiring an additional 23,027 shares and bringing its total holdings to 73,419 shares valued at approximately $2.3 million. Despite the company missing its latest earnings …

HC Wainwright Has Bearish Forecast for EWTX Q3 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages

Edgewise Therapeutics (NASDAQ:EWTX) has received a "Moderate Buy" consensus rating from eleven research firms, with an average 12-month price target of $48.75. The company recently reported a quarterly loss of $0.53 per share, missing consensus estimates, and insider Alan J. Russell sold a significant …

Edgewise Therapeutics Inc (EWTX) Stock News Today

Edgewise Therapeutics stock hits all-time high at 43.96 USD

Edgewise Therapeutics (EWTX) stock reached an all-time high of $43.96, currently trading at $44.17 with a market capitalization of $4.66 billion, reflecting a 231% increase over the past year. Despite this surge, InvestingPro data suggests the stock may be overvalued relative to its Fair …

Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history

This page provides a comprehensive overview of Edgewise Therapeutics, Inc. (EWTX), including its current stock price, financial summary, historical data, and recent news. The company is a biopharmaceutical firm focused on developing therapies for muscle disorders, with lead product candidates like sevasemten for muscular …

Edgewise Therapeutics, Inc. Stock 12‑Month Price Target Raised to $50.46, Implies 12% Upside

Analysts have raised the average 12-month price target for Edgewise Therapeutics, Inc. (EWTX) stock to $50.46, up from $49.92, suggesting a 12% potential upside based on the Aug. 5 closing price. The consensus rating from 13 covering analysts remains a "Buy," with 11 Buy …

Edgewise Therapeutics (NASDAQ:EWTX) Posts Earnings Results, Misses Estimates By $0.06 EPS

Edgewise Therapeutics 2Q 2026: Net loss $57.3M, EPS ($0.53) — 10-Q Summary

Edgewise Therapeutics reported a net loss of $57.3M, or $0.53 per diluted share, for Q2 2026, an increase from $36.1M in the prior year. The company is strategically shifting its focus to its cardiovascular pipeline after selling its muscular dystrophy asset, sevasemten, to Servier …

FMR LLC discloses 5.1% Edgewise Therapeutics (EWTX) holding in Schedule 13G

Edgewise Therapeutics Q2 net loss widens to $57.3 million

Edgewise Therapeutics (EWTX) reported a widened net loss of $57.3 million, or $0.53 per share, for Q2 2026, compared to $36.1 million in Q2 2025. This comes as the company's research and development expenses increased to $47.5 million. The report also highlights insider selling …

Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

Edgewise Therapeutics announced its second-quarter 2026 financial results, highlighted by positive top-line data from its

Edgewise Therapeutics Inc (EWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Edgewise Therapeutics earnings up next after HCM data, Servier deal By Investing.com

Edgewise Therapeutics is set to release its second-quarter results, with analysts anticipating a loss of $0.47 per share. The company recently agreed to sell its muscular dystrophy business to Servier for $1.55 billion and announced positive Phase 2 trial results for EDG-7500 in hypertrophic …

Edgewise Therapeutics gains as investors weigh cash-rich reset and cardiovascular pipeline progress

Edgewise Therapeutics (EWTX) stock increased by 16.5% due to sustained investor confidence in its financial stability and refined cardiovascular strategy, following the sale of its muscular dystrophy business for $1.55 billion upfront. This transaction is expected to fund the development of EDG-7500 through approval, …

Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Still a Buy?

Enterprise value to EBIT forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX

The article focuses on the enterprise value to EBIT forward metric for Edgewise Therapeutics, Inc. (NASDAQ: EWTX). It appears to be a financial data point or a report available on the TradingView platform, specifically within the financial overview for the company.

(EWTX) Price Dynamics and Execution-Aware Positioning

The article provides a detailed analysis of Edgewise Therapeutics Inc. (NASDAQ: EWTX) using AI models, highlighting a mixed sentiment with near-term positive and mid-term weak biases

Healthcare of Ontario Pension Plan Trust Fund Sells 236,200 Shares of Edgewise Therapeutics, Inc. $EWTX

Edgewise Therapeutics Inc (EWTX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Edgewise Therapeutics Inc (EWTX), focusing on its stock price, market capitalization, and key financial ratios like P/E, P/B, and P/CF. It notes that relevant data for these ratios have not yet been disclosed by the company. The …